Search | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Promising news for older AML patients

    ... was effective among patients with both primary de novo AML (68%) and secondary AML (related to myelodysplasia or ...

    Article last updated 07/19/2017 - 11:19am.

  2. Tea consumption reduces the risk of de novo myelodysplastic syndromes

    ... the association between tea intake and the risk of de novo MDS in adults. The study included 208 cases aged 19-85 years with MDS ...

    Research Article last updated 01/20/2015 - 12:56pm.

  3. Allogeneic hematopoetic stem cell transplantation in pediatric myelodysplastic syndromes: Improved outcomes for de novo disease.

    ... myelodysplastic syndromes : Improved outcomes for de novo disease. Pediatr Transplantation 2011: 15: 334-343. © 2011 John ...

    Research Article last updated 10/11/2011 - 5:58pm.

  4. Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium.

    ... syndromes (MDS) have worse outcomes than de novo MDS (d-MDS), some t-MDS patients have an indolent course. Most MDS ...

    Research Article last updated 03/09/2017 - 1:27pm.

  5. TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases

    ... in therapy-related myeloid neoplasms (t-MN) than their de novo counterparts; however, the pattern of mutations involving TP53 gene ...

    Research Article last updated 06/03/2015 - 1:04pm.

  6. Focal Adhesion Kinase as a Potential Target in AML and MDS

    ... who transformed from MDS compared with those with de novo AML. Co-culture with mesenchymal stromal cells (MSCs) increased FAK ...

    Research Article last updated 03/22/2017 - 10:20am.

  7. Role of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem-Cell Transplantation in Older Patients With De Novo Myelodysplastic Syndromes: An International Collaborative Decision Analysis.

    ... life expectancy (QALE). A total of 514 patients with de novo MDS aged 60 to 70 years were evaluated. Chronic myelomonocytic ...

    Research Article last updated 07/09/2013 - 3:28pm.

  8. Evaluation of epidemiological factors in survival of patients with de novo myelodysplastic syndromes

    ... markers as predictors of survival for 365 adult de novo MDS patients. Multivariable Cox regression analysis was used to ...

    Research Article last updated 02/04/2014 - 1:43pm.

  9. Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs. de novo myelodysplastic syndromes: A report on behalf of the MDS clinical research consortium

    ... While therapy-related (t)-MDS has worse outcomes than de novo MDS (d-MDS), some t-MDS patients have an indolent course. Most MDS ...

    Research Article last updated 02/03/2017 - 10:09am.

  10. Association of Therapy for Autoimmune Disease With Myelodysplastic Syndromes and Acute Myeloid Leukemia

    ... 72.3 [15.6] years), 55 (64.0%) had MDS, 21 (24.4%) had de novo AML, and 10 (11.6%) had AML and a history of MDS. Rheumatoid arthritis ...

    Research Article last updated 02/21/2017 - 10:55am.